• This record comes from PubMed

Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and mild or moderate hepatic impairment

. 2020 Sep ; 86 (9) : 1807-1818. [epub] 20200405

Language English Country Great Britain, England Media print-electronic

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/pmid32227355

Grant support
AstraZeneca - International
Merck Sharp & Dohme Corp. - International
Merck & Co., Inc. - International

AIMS: Olaparib, a potent oral poly(ADP-ribose) polymerase inhibitor, is partially hepatically cleared. We investigated the pharmacokinetics (PK) and safety of olaparib in patients with mild or moderate hepatic impairment to provide dosing recommendations. METHODS: This Phase I open-label study assessed the PK, safety and tolerability of single doses of olaparib 300-mg tablets in patients with advanced solid tumours. Patients had normal hepatic function (NHF), or mild (MiHI; Child-Pugh class A) or moderate (MoHI; Child-Pugh class B) hepatic impairment. Blood was collected for PK assessments for 96 hours. Patients could continue taking olaparib 300 mg twice daily for long-term safety assessment. RESULTS: Thirty-one patients received ≥1 dose of olaparib and 30 were included in the PK assessment. Patients with MiHI had an area under the curve geometric least-squares mean (GLSmean) ratio of 1.15 (90% confidence interval 0.72, 1.83) and a GLSmean maximum plasma concentration ratio of 1.13 (0.82, 1.56) vs those with NHF. In patients with MoHI, GLSmean ratio for area under the curve was 1.08 (0.66, 1.74) and for maximum plasma concentration was 0.87 (0.63, 1.22) vs those with NHF. For patients with mild or moderate hepatic impairment, no new safety signals were detected. CONCLUSION: Patients with MiHI or MoHI had no clinically significant changes in exposure to olaparib compared with patients with NHF. The safety profile of olaparib did not differ from a clinically relevant extent between cohorts. No olaparib tablet or capsule dose reductions are required for patients with MiHI or MoHI.

See more in PubMed

Gunderson CC, Moore KN. Olaparib: an oral PARP‐1 and PARP‐2 inhibitor with promising activity in ovarian cancer. Future Oncol. 2015;11(5):747‐757. PubMed

European Medicines Agency . Lynparza (olaparib): An overview of Lynparza and why it is authorised in the EU. 2019. Available at: https://www.ema.europa.eu/en/documents/overview/lynparza-epar-medicine-overview_en.pdf.

European Medicines Agency . Lynparza summary of product characteristics. 2014. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003726/WC500180151.pdf

FDA . Lynparza prescribing information. 2014. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206162lbl.pdf.

European Medicines Agency . CHMP assessment report on extension of marketing authorisation grouped with a variation: Lynparza. 2018. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/003726/WC500249582.pdf

FDA . Lynparza prescribing information (revised September 2018). 2018. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208558s006lbl.pdf.

FDA . Guidance for industry. Pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling. 2003. Available at: https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm072123.pdf

European Medicines Agency . Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with impaired hepatic function. 2005. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-evaluation-pharmacokinetics-medicinal-products-patients-impaired-hepatic-function_en.pdf

Ang JE, Clarkson‐Jones JA, Swaisland H, et al. A mass balance study to investigate the metabolism, excretion and pharmacokinetics of [14C]‐olaparib (AZD2281) in patients with advanced solid tumours refractory to standard treatments. Eur J Cancer Suppl. 2010;8(7):128‐129.

Superfin D, Iannucci AA, Davies AM. Commentary: oncologic drugs in patients with organ dysfunction: a summary. Oncologist. 2007;12(9):1070‐1083. PubMed

Dirix L, Swaisland H, Verheul HMW, et al. Effect of itraconazole and rifampin on the pharmacokinetics of olaparib in patients with advanced solid tumors: results of two phase I open‐label studies. Clin Ther. 2016;38(10):2286‐2299. PubMed

Rolfo C, Swaisland H, Leunen K, et al. Effect of food on the pharmacokinetics of olaparib after oral dosing of the capsule formulation in patients with advanced solid tumors. Adv Ther. 2015;32(6):510‐522. PubMed

AstraZeneca . Global policy: bioethics. 2016. Available at: https://www.astrazeneca.com/content/dam/az/PDF/2016/Bioethics_policy.pdf

Mateo J, Moreno V, Gupta A, et al. An adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparib. Target Oncol. 2016;11(3):401‐415. PubMed

Rolfo C, de Vos‐Geelen J, Isambert N, et al. Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and renal impairment. Clin Pharmacokinet. 2019;58(9):1165‐1174. PubMed

FDA . Cancer clinical trial eligibility criteria: patients with organ dysfunction or prior or concurrent malignancies guidance for industry. 2019. Available at: https://www.fda.gov/media/123745/download.

Talal AH, Venuto CS, Younis I. Assessment of hepatic impairment and implications for pharmacokinetics of substance use treatment. Clin Pharmacol Drug Dev. 2017;6(2):206‐212. PubMed PMC

Palatini P, De Martin S. Pharmacokinetic drug interactions in liver disease: an update. World J Gastroenterol. 2016;22(3):1260‐1278. PubMed PMC

Pilla Reddy V, Bui K, Scarfe G, Zhou D, Learoyd M. Physiologically based pharmacokinetic modeling for olaparib dosing recommendations: bridging formulations, drug interactions, and patient populations. Clin Pharmacol Ther. 2019;105(1):229‐241. PubMed PMC

Zhou D, Li J, Learoyd M, et al. Efficacy and safety exposure‐response analysis of olaparib capsule and tablet formulations in oncology patients. Clin Pharmacol Ther. 2019;105(6):1492‐1500. PubMed

Johnson TN, Boussery K, Rowland‐Yeo K, Tucker GT, Rostami‐Hodjegan A. A semi‐mechanistic model to predict the effects of liver cirrhosis on drug clearance. Clin Pharmacokinet. 2010;49(3):189‐206. PubMed

Bupsilondingen FV, Gonzalez D, Tucker AN, Derendorf H. Relevance of liver failure for anti‐infective agents: from pharmacokinetic alterations to dosage adjustments. Ther Adv Infect Dis. 2014;2(1):17‐42. PubMed PMC

Ono C, Hsyu PH, Abbas R, Loi CM, Yamazaki S. Application of physiologically based pharmacokinetic modeling to the understanding of bosutinib pharmacokinetics: prediction of drug‐drug and drug‐disease interactions. Drug Metab Dispos. 2017;45(4):390‐398. PubMed

Sarfeh IJ, Aaronson S, Lombino D, et al. Selective impairment of nutrient absorption from intestines with chronic venous hypertension. Surgery. 1986;99(2):166‐169. PubMed

Bui K, She F, Sostek M. The effects of mild or moderate hepatic impairment on the pharmacokinetics, safety, and tolerability of naloxegol. J Clin Pharmacol. 2014;54(12):1368‐1374. PubMed

Khalilieh S, Yee KL, Liu R, et al. Moderate hepatic impairment does not affect doravirine pharmacokinetics. J Clin Pharmacol. 2017;57(6):777‐783. PubMed

Friedlander M, Matulonis U, Gourley C, et al. Long‐term efficacy, tolerability and overall survival in patients with platinum‐sensitive, recurrent high‐grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. Br J Cancer. 2018;119(9):1075‐1085. PubMed PMC

Pujade‐Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum‐sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT‐Ov21): a double‐blind, randomised, placebo‐controlled, phase 3 trial. Lancet Oncol. 2017;18(9):1274‐1284. PubMed

Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523‐533. PubMed

Find record

Citation metrics

Archiving options